Skip to main content

Table 2 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy complication, using G0/G2 chromosomal assay

From: Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays

Reference Marker Sample size Cell type Radiation dose Result
Breast cancer
 Ryabchenk et al. 2012 [148] G0 and G2 chromosomal assay 1. BC cases (37) Lymphocyte G0 assay G0 assay & G2 assay
2. Healthy controls (44) 1.5 Gy Spontaneous RS
X-rays BC cases ↔ Healthy controls
G2 assay G0 assay & G2 assay
0.5 Gy RS after radiation
X-rays BC cases > Healthy controls
 Bryant et al. 2012 [151] G2 chromosomal assay 1. BC cases (89) Lymphocyte 0.4 Gy RS after radiation
2. Healthy controls (96) γ-rays BC cases > Healthy controls
 Wang et al. (2012) [152] G2 chromosomal assay 1. BC cases (515) Lymphocyte 1.5 Gy non-Hispanic White
2. Healthy controls (402) γ-rays BC cases > Healthy control
Mexican American
BC cases > Healthy control
African Americans
BC cases ↔ Healthy controls
 Poggioli et al. 2010 [150] G0 & G2 chromosomal assay 1. BC cases (23) Lymphocyte G2 assay G0 assay & G2 assay
2. Healthy controls (23) 0.4 Gy Spontaneous RS
X-rays BC cases ↔ Healthy controls
G0 assay G0 assay & G2 assay
2 Gy RS after radiation
X-rays BC cases > Healthy controls
G2 assay could be more appropriate to define the individual RS if compare with G0 assay
 Howe et al. 2005 [149] G2 chromosomal assay 1. BC cases (27) Lymphocyte 0.5 Gy RS after radiation
2. Healthy controls (14) γ-rays BC cases > Healthy controls
 Riches et al. 2001 [147] G2 chromosomal assay 1. BC cases (65) Lymphocyte 0.4 Gy RS after radiation
2. Healthy controls (66) γ-rays BC cases > Healthy controls
 Scott et al. 1999 [135] G2 chromosomal assay 1. BC cases (135) Lymphocyte 0.5 Gy Spontaneous RS
2. Healthy controls (105) X-rays Healthy control ↔ BC cases
RS after radiation
BC cases > Healthy controls
BRCA1/2 mutation
 Ernestos et al. 2010 [153] G2 chromosomal assay 1. BC cases with BRCA1/2 mutation (15) Lymphocyte 1 Gy RS after radiation
2. Healthy BRCA1/2 mutation carriers (5) γ-rays BC with BRCA1/2 mutation > Healthy controls
3. Healthy controls W/O familial history of cancer (21) Healthy BRCA1/2 mutation carriers > Healthy controls
 Baeyens et al (2002) [139] G2 chromosomal assay 1. BC cases with BRCA1/2 mutation (20) Lymphocyte 0.4 Gy Spontaneous RS
 A. BRCA1(11) γ-rays No difference across all groups
 B. BRCA2 (9) RS after radiation
2. Healthy relatives with BRCA mutation (12) BC with BRCA1 mutation ↔ BC W/O BRCA mutation ↔ healthy controls
 A. BRCA1 (6) BC with BRCA2 mutation > healthy controls
 B. BRCA2 (6) Healthy relatives with and W/O a BRCA1 mutation ↔ healthy controls
3. Healthy relatives W/O BRCA mutation (10)
 A. of BRCA1 (5)
 B. of BRCA2 (5)
4. BC cases W/O BRCA mutation (78)
5. Healthy controls (58)
Radiotherapy complications
 Finnon et al. 2012 [143] G2 chromosomal assay 1. BC cases with marked reaction (31) Lymphocyte 3.5 Gy RS after radiation
2. BC cases with mild late adverse reaction (28) X-rays Marked reaction ↔ Mild late adverse reaction
 Barber et al. 2000 [134] G2 chromosomal assay HDR
Acute reactions before radiotherapy (116)
Late reactions, 8-14 years after radiotherapy (47)
LDR
Acute reactions before radiotherapy (73)
Late reactions, 8-14 years after radiotherapy (26)
Lymphocyte HDR HDR
3.5 Gy γ-rays (dose rate 1.0 Gy min-1) RS after radiation
Acute reactions before radiotherapy ↔ 8-14 years after radiotherapy
LDR
3.5 Gy γ-rays (dose rate 0.15 Gy min-1) LDR
RS after radiation
Acute reactions before radiotherapy ↔ 8-14 years after radiotherapy
  1. RS radiosensitivity, BC breast cancer, HDR high dose rate, LDR low dose rate, W/O without, Gr gray
  2. ↔: no significant differences at the radiosensitivity level, >: significant higher level of radiosensitivity